^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ERAS-007

i
Company:
Asana BioSci, Erasca, UT MD Anderson Cancer Center
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Phase 1/2
Erasca, Inc.
Active, not recruiting
Last update posted :
02/11/2025
Initiation :
09/20/2021
Primary completion :
08/01/2025
Completion :
12/01/2025
KRAS • BRAF • NRAS
|
BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
|
Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
Phase 1b
Erasca, Inc.
Completed
Last update posted :
07/25/2023
Initiation :
09/02/2021
Primary completion :
04/27/2023
Completion :
04/27/2023
KRAS
|
KRAS mutation • EGFR mutation • KRAS G12C
|
Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
Phase 1b/2
Erasca, Inc.
Withdrawn
Last update posted :
06/15/2022
Initiation :
03/15/2022
Primary completion :
03/01/2025
Completion :
06/01/2025
FLT3
|
FLT3 mutation
|
Xospata (gilteritinib) • ERAS-007 • ERAS-601
Phase 1
Asana BioSciences
Completed
Last update posted :
07/09/2020
Initiation :
01/19/2018
Primary completion :
06/30/2020
Completion :
06/30/2020
KRAS • HRAS
|
KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation
|
ERAS-007